Neuland Labs reports strong Q2FY26 standalone results with significant revenue and PAT growth
Neuland Labs reported strong Q2FY26 standalone results, with revenue up 63.7% to ₹516.1 crore and PAT up 201.6% to ₹96.5 crore, driven by CMS projects and operational improvements.
The announcement details strong financial performance for Q2FY26, strategic operational achievements like a successful FDA inspection, and positive management outlook, which are all significant factors influencing investor perception and future stock performance.
The company reported significant year-on-year growth in total income, EBITDA, and PAT for Q2FY26, with positive management commentary on continued momentum and strategic positioning for future growth in both CDMO and generic APIs.
Neuland Laboratories Limited has released its Investor/Analysts Presentation detailing the standalone financial results for the quarter and half year ended September 30, 2025. Key highlights are as follows: * Q2FY26 Financial Highlights (Standalone): * Total Income increased by 63.7% year-on-year (YoY) to ₹516.1 crore. * EBITDA grew by 138.8% YoY to ₹156.9 crore, with EBITDA Margin expanding by 960 basis points (bps) to 30.4%. * Profit After Tax (PAT) surged by 201.6% YoY to ₹96.5 crore, with PAT Margin at 18.7%. * Net Debt stood at ₹(-6.6) crore at the end of Q2FY26, an improvement from ₹(-94.3) crore in Q2FY25. * H1FY26 Financial Highlights (Standalone): * Total Income rose by 7.5% YoY to ₹816.7 crore. * EBITDA increased by 2.5% YoY to ₹199.1 crore, with EBITDA Margin at 24.4%. * PAT was ₹110.2 crore, a decrease of 15.4% YoY. * Management Commentary: * Sucheth Davuluri noted record high revenue driven by CMS commercial projects, leading to operating leverage in EBITDA margins, and anticipates continued momentum. The company is well-positioned for growth in both CDMO and generic APIs. * Saharsh Davuluri highlighted increased customer interest and engagement, with Neuland's reputation as an agile partner driving new business and greater share from existing customers. Investments are proceeding as planned to further differentiate the company. * Operational Highlights: * Unit-2 received an Establishment Inspection Report (EIR) following an FDA inspection in Q1. * One US Drug Master File (USDMF) was filed in Q2 FY26. * Unit-1 was awarded the Sword of Honour from the British Safety Council for outstanding Health & Safety practices. * Business Performance: * CMS revenues were driven by commercial molecules, with growth in new project orders. * In the GDS Prime segment, Ezetimibe and Mirtazapine were key molecules, with Ezetimibe expected to drive growth. * The Specialty business was subdued, with revenue primarily from sterile products. * Capex outflow for H1FY26 amounted to ₹170 crore.
What to do with a filing like this
Neuland Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Neuland Laboratories Limited. Read the original for the full detail.